A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.
about
Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart AssociationOral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksOral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksAntiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacksOral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacksClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsAnticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?Epidemiology, diagnosis, and management of atrial fibrillation in womenPosttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatmentEffects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillationOptimising stroke prevention in non-valvular atrial fibrillationA cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke preventionHeart disease and stroke statistics--2011 update: a report from the American Heart AssociationHeart disease and stroke statistics--2014 update: a report from the American Heart AssociationHeart disease and stroke statistics--2012 update: a report from the American Heart AssociationStroke Risk Factors, Genetics, and Prevention.Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationDetecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke.The golden age of minimally invasive cardiothoracic surgery: current and future perspectives.Risk assessment for incident heart failure in individuals with atrial fibrillation.Insertable cardiac monitors in the diagnosis of syncope and the detection of atrial fibrillation: A systematic review and meta-analysis.Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.Sex Differences in Outcomes among Stroke Survivors with Non-Valvular Atrial Fibrillation in China.Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysisUse of evidence-based cardiac prevention therapy among outpatients with atrial fibrillationExtreme deep white matter hyperintensity volumes are associated with African American raceIndividualized medical decision making: necessary, achievable, but not yet attainable.Why do authors derive new cardiovascular clinical prediction rules in the presence of existing rules? A mixed methods study.An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.Linking brain stroke risk factors to human movement features for the development of preventive tools.Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-makingAtrial fibrillation in congestive heart failure.The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study.Development of a tool to improve the quality of decision making in atrial fibrillation.Current perceptions of the epidemiology of atrial fibrillation.A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice.Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patientsAntithrombotic therapy in cardiac embolism.A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation
P2860
Q22306356-467F5F31-9451-498C-930A-5678A9886B94Q24244298-1D5A16B1-3A0C-4468-83E8-CE44F135F000Q24244742-C435F776-B9C9-44FE-A9EF-D59EF6AEF47EQ24245569-23B4B48E-695A-4278-8554-42610500F593Q24246644-24AEC0D0-4CB4-4481-B681-6330652EF9DDQ26828817-46DB1863-34E2-466F-9961-CD2CD2F252A4Q27010464-9D94B9FC-4341-4BB4-A8D5-7774D1351E70Q28083655-B5912C2E-7D2D-45A7-AAB4-D8672CFD446FQ28085335-8B0F3E6B-E995-4186-9514-6DB39FB1F8BBQ28175492-242A0008-DE1E-4255-B86C-C606BE6392BEQ28200609-B4502A95-00BE-47AD-A7D7-C68BCD3B9D5BQ28218659-01B77069-1B95-4FBF-A144-6542A787FD6BQ29547236-213253BA-7927-4FF9-BF60-240229B220AAQ29547691-E2F6E613-2BFB-45F3-91D0-97A4848F4F17Q29547909-63015E85-BB1E-4B26-AA3B-579082FD8547Q30238633-4CBFC88A-6E6A-410C-A3DC-9AC3323A7C77Q30238784-A905A8DE-3026-48AF-BF43-1E91DA8C323DQ30249817-D1BB5EDB-B5A4-4C24-8FA7-C17FB4A6AF5CQ30469960-D6A76F18-4C6A-4F82-97C6-1F7DC7BDB2C7Q30559212-67AA7B0B-A367-4071-8674-EB7D4172D31EQ33166805-D35215C2-266B-4B8E-9EA9-E123BFBD7A43Q33232061-719188E7-B7AC-4A85-BC3D-0F4DEA70DAB3Q33606961-FD08221E-12C4-462F-BFB8-25BA18DC4B04Q33663474-A9EAFF41-88F9-43EB-9913-4B9DC7A2E8EBQ33680031-3EF6AAC8-192B-4A8B-BA58-C0550B0B37D8Q33745467-DA8A4A14-EF4E-41FB-8497-12156ADAE116Q33752536-70B53DCB-4A1B-44B0-A3EC-E8FD4C63E334Q33773250-60FE4236-0B5E-45D0-A570-EC9456292FF7Q33811339-DE4F7913-243D-4F90-ACE0-065292E78CFAQ33858235-EA75BF40-7210-4D39-AB23-8D7C1014186CQ33911981-23553322-03EE-4EB7-9D66-C962326AC08CQ33949571-FCDE4601-C4C9-40C6-BB32-BBA7BA762293Q33954432-BB30C084-588E-49CA-9361-E549264B41BAQ34008166-4FAE08AA-92C8-4207-B94E-28DE77D9671EQ34041787-94F61E7A-FB14-4706-83DB-BD61DBD0C5BAQ34048260-D59135FB-4914-44ED-A804-B1C2FD7D590FQ34146593-AB725008-27F7-47EE-8807-580BBC2E5CCBQ34177673-FFF474D3-56F0-48ED-9E6C-5963C4F5ADF8Q34362901-BC5DB9D3-DB60-4614-A5DD-40B597794E55Q34434368-3582BF66-AEAD-4DA9-9380-3EF71AC7F80A
P2860
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A risk score for predicting st ...... y: the Framingham Heart Study.
@ast
A risk score for predicting st ...... y: the Framingham Heart Study.
@en
A risk score for predicting st ...... y: the Framingham Heart Study.
@nl
type
label
A risk score for predicting st ...... y: the Framingham Heart Study.
@ast
A risk score for predicting st ...... y: the Framingham Heart Study.
@en
A risk score for predicting st ...... y: the Framingham Heart Study.
@nl
prefLabel
A risk score for predicting st ...... y: the Framingham Heart Study.
@ast
A risk score for predicting st ...... y: the Framingham Heart Study.
@en
A risk score for predicting st ...... y: the Framingham Heart Study.
@nl
P2093
P50
P356
P1476
A risk score for predicting st ...... y: the Framingham Heart Study.
@en
P2093
Daniel Levy
Ralph B D'Agostino
Thomas J Wang
William B Kannel
P304
P356
10.1001/JAMA.290.8.1049
P407
P577
2003-08-01T00:00:00Z